Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study

Gastric Cancer

Volumn 20, Issue 2, 2017, Pages 332-340

  Fuse, Nozomu ^a   Bando, Hideaki ^a   Chin, Keisho ^b   Ito, Seiji ^c   Yoshikawa, Takaki ^d   Tsuburaya, Akira ^d   Terashima, Masanori ^e   Kawashima, Yoshiyuki ^f   Fukunaga, Tetsu ^g   Gotoh, Masahiro ^h   Emi, Yasunori ⁱ   Yoshida, Kazuhiro ^j   Oki, Eiji ^k   Takahashi, Seiji ^l   Kuriki, Hiroshi ^m   Sato, Kumi ^m   Sasako, Mitsuru ⁿ  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA MEDICAL COLLEGE   (Japan)

ⁱ SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^j GIFU UNIVERSITY   (Japan)

^k KYUSHU UNIVERSITY HOSPITAL   (Japan)

^l YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^m CHUGAI PHARMACEUTICAL CO LTD   (Japan)

ⁿ HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Adjuvant treatment; Feasibility study; Gastric cancer; Japanese study; XELOX

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CANCER ADJUVANT THERAPY; CHINESE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTRECTOMY; HAND FOOT SYNDROME; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; POSTOPERATIVE CARE; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SOUTH KOREAN; STOMACH CANCER; STOMATITIS; TAIWANESE; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84962030324     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-016-0606-4     Document Type: Article

References (18)

1. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/bar_site.asp?selection=25050&title=Stomach&sex=0&statistic=2&populations=5&window=1&grid=1&info=1&orientation=1&color1=5&color1e=&color2=4&color2e=&submit=%C2%A0Execute.
2. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.
3. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40:584–91.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.
5. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.
6. National Comprehensive Cancer Network (2015) Clinical practice: guidelines in oncology. Gastric Cancer version 3, 2015.
7. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.
8. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol. 2004;22:2069–77.
9. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
10. Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014;20:13718–27.
11. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
12. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
13. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.
14. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.
15. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423–8.
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
17. Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2010;40:913–20.
18. He J, Wen F, Yin X, Zhang P, Du Z, He X, et al. Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anticancer Drugs. 2013;24:754–8.